Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21059489 | 1.00 | TSHR (0.62) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL30287862 | 0.99 | TSHR (0.61) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL21059453 | 0.90 | TSHR (0.68) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL21059454 | 0.90 | TSHR (0.68) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL13603780 | 0.87 | TSHR (0.68) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL11094619 | 0.82 | PPARA (0.43) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL1332738 | 0.81 | TSHR (0.59) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL11835348 | 0.79 | TSHR (0.57) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| (S)-Dichlorprop SCHEMBL1535831 | 0.79 | TSHR (0.73) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| Rac-Dichlorprop SCHEMBL54510 | 0.79 | TSHR (0.73) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491628-B | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-10-13 | — | — | CN | claimed |
| EP-3723746-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2022-02-23 | — | — | EP | claimed |
| EP-3723746-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| CN-111491628-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-04 | — | — | CN | claimed |
| WO-2019115780-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | claimed |
| CN-111491628-B | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-02-28 | — | — | US | disclosed |
| EP-3723746-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| EP-3723746-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111491628-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2019115780-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | TSHR 3912/4885HTR2A 3420/4885HTR2C 3861/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, CACNA1S | TSHR 4324/4885HTR2A 3734/4885HTR2C 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.